<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BRN</journal-id>
<journal-id journal-id-type="hwp">spbrn</journal-id>
<journal-id journal-id-type="nlm-ta">Biol Res Nurs</journal-id>
<journal-title>Biological Research For Nursing</journal-title>
<issn pub-type="ppub">1099-8004</issn>
<issn pub-type="epub">1552-4175</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1099800411405031</article-id>
<article-id pub-id-type="publisher-id">10.1177_1099800411405031</article-id>
<title-group>
<article-title>Effect of Obesity on Cardiovascular Disease Risk Factors in African American Women</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Henry-Okafor</surname>
<given-names>Queen</given-names>
</name>
<degrees>PhD, FNP-BC</degrees>
<xref ref-type="aff" rid="aff1-1099800411405031">1</xref>
<xref ref-type="corresp" rid="corresp1-1099800411405031"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cowan</surname>
<given-names>Patricia A.</given-names>
</name>
<degrees>PhD, RN</degrees>
<xref ref-type="aff" rid="aff2-1099800411405031">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wicks</surname>
<given-names>Mona N.</given-names>
</name>
<degrees>PhD, RN</degrees>
<xref ref-type="aff" rid="aff2-1099800411405031">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rice</surname>
<given-names>Muriel</given-names>
</name>
<degrees>PhD, RN</degrees>
<xref ref-type="aff" rid="aff3-1099800411405031">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Husch</surname>
<given-names>Donna S.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff4-1099800411405031">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Khoo</surname>
<given-names>Michelle S. C.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5-1099800411405031">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-1099800411405031"><label>1</label>Cardiovascular Medicine, Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN</aff>
<aff id="aff2-1099800411405031"><label>2</label>College of Nursing, University of Tennessee Health Science Center, Memphis, TN</aff>
<aff id="aff3-1099800411405031"><label>3</label>Family Planning, Memphis Shelby County Health Department, Memphis, TN</aff>
<aff id="aff4-1099800411405031"><label>4</label>Department of Statistics, Operations, &amp; Management Science, University of Tennessee, Knoxville, Knoxville, TN</aff>
<aff id="aff5-1099800411405031"><label>5</label>Division of Cardiology, Section of Cardiac Electrophysiology, University of Colorado, Aurora, Colorado</aff>
<author-notes>
<corresp id="corresp1-1099800411405031">Queen Henry-Okafor, PhD, FNP-BC, Division of Cardiovascular Medicine, 2220 Pierce Avenue, 383 PRB, Nashville, TN 37232, USA Email: <email>queen.o.henry-okafor@vanderbilt.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>14</volume>
<issue>2</issue>
<fpage>171</fpage>
<lpage>179</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Obesity is a growing health care concern with implications for cardiovascular disease (CVD). Obesity and CVD morbidity and mortality are highly prevalent among African American women. This pilot study examined the association between obesity and the traditional and emerging CVD risk factors in a sample of African American women. Participants comprised 48 women (27 obese, 21 normal weight) aged 18–45. with no known history of CVD. The women completed demographic and 7-day physical activity recall questionnaires. Height and weight were used to determine body mass index (BMI). Hypertension risk was assessed using the average of two resting blood pressure (BP) measurements. Lipid profile, blood glucose, fibrinogen, high-sensitivity C-reactive protein (hs-CRP), plasminogen activator inhibitor-1 (PAI-1), soluble intercellular adhesion molecule-1 (sICAM-1), and E-selectin (eSel) levels were assessed using fasting blood samples. Laboratory findings were interpreted using the American Diabetes Association (ADA) and Adult Treatment Panel (ATP) III reference guidelines as well as manufacturers’ reference ranges for the novel CVD risk factors. The most common traditional risk factors were physical inactivity (72.9%), positive family history of CVD (58.3%), and obesity (56.3%). Obese individuals had elevated systolic BP (<italic>p</italic> = .0002), diastolic BP (<italic>p</italic> = .0007) and HDL-cholesterol (<italic>p</italic> = .01), triglyceride (<italic>p</italic> = .02), hs-CRP (<italic>p</italic> = .002), and fibrinogen (<italic>p</italic> = .01), when compared with normal-weight women. The findings suggest an association between obesity and higher prevalence of both traditional and emerging CVD risk factors in young African American women.</p>
</abstract>
<kwd-group>
<kwd>cardiovascular disease</kwd>
<kwd>emerging risk factors</kwd>
<kwd>traditional risk factors</kwd>
<kwd>African American women</kwd>
<kwd>obesity</kwd>
<kwd>prevalence rate</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Obesity is a major cause of preventable deaths in the United States as well as a potent risk factor for cardiovascular disease (CVD), with atherosclerotic CVD as its foremost consequence (<xref ref-type="bibr" rid="bibr28-1099800411405031">Grundy, Hansen, Smith, Cleeman, &amp; Kahn, 2004</xref>; <xref ref-type="bibr" rid="bibr44-1099800411405031">Nelson et al., 2002</xref>). Multiple studies have documented the associations between obesity and CVD risk factors (<xref ref-type="bibr" rid="bibr21-1099800411405031">Flegal, 2000</xref>; <xref ref-type="bibr" rid="bibr36-1099800411405031">Li et al., 2008</xref>; <xref ref-type="bibr" rid="bibr44-1099800411405031">Nelson et al., 2002</xref>). The prevalence of obesity among American adults based on the World Health Organization’s classification scheme (BMI ≥ 30 kg/m<sup>2</sup>) is about 22% (<xref ref-type="bibr" rid="bibr22-1099800411405031">Flegal, Carroll, Kuczmarski, &amp; Johnson, 1998</xref>; <xref ref-type="bibr" rid="bibr55-1099800411405031">Taylor et al., 2009</xref>; <xref ref-type="bibr" rid="bibr58-1099800411405031">Weisell, 2002</xref>), a rate that has doubled over the last two decades. Despite overwhelming evidence about its consequences, obesity remains a growing epidemic among many racial and ethnic minorities in the United States and is a major public health concern (<xref ref-type="bibr" rid="bibr40-1099800411405031">Mello, Studdert, &amp; Brennan, 2006</xref>). Obesity affects over a third of women, with African American women having the highest prevalence rate (<xref ref-type="bibr" rid="bibr32-1099800411405031">Hill &amp; Peters, 1998</xref>; <xref ref-type="bibr" rid="bibr41-1099800411405031">Mensah et al., 2004</xref>; <xref ref-type="bibr" rid="bibr42-1099800411405031">Mokdad et al., 2003</xref>). At similar levels of adiposity, African American women have more obesity-related diseases compared to other ethnic minorities (<xref ref-type="bibr" rid="bibr13-1099800411405031">Cossrow &amp; Falkner, 2004</xref>; <xref ref-type="bibr" rid="bibr44-1099800411405031">Nelson et al., 2002</xref>; <xref ref-type="bibr" rid="bibr55-1099800411405031">Taylor et al., 2009</xref>). The purpose of this study was to describe the relationship between body mass index (BMI) and traditional and emerging CVD risk factors in African American women aged 18–45 who had no known history of CVD. The principal hypothesis that guided this study was that higher BMI is associated with higher levels of these risk factors.</p>
<p>Contrary to the previously held assumption that CVD affects primarily men and the elderly, CVD has become the leading cause of death among women in the United States, particularly among African American women (<xref ref-type="bibr" rid="bibr23-1099800411405031">Flegal, Carroll, Ogden, &amp; Johnson, 2002</xref>; <xref ref-type="bibr" rid="bibr29-1099800411405031">Hedley et al., 2004</xref>). Similarly, it was previously accepted that CVD occurs because of lipid abnormalities (<xref ref-type="bibr" rid="bibr3-1099800411405031">Alagona, 2009</xref>; <xref ref-type="bibr" rid="bibr15-1099800411405031">Despres, Arsenault, Cote, Cartier, &amp; Lemieux, 2008</xref>; <xref ref-type="bibr" rid="bibr28-1099800411405031">Grundy et al., 2004</xref>). The evidence suggested that high low-density lipoprotein (LDL)-cholesterol concentrations initiate atherogenesis and promote atherosclerosis, whereas a high high-density lipoprotein (HDL)-cholesterol level has been described as cardioprotective (<xref ref-type="bibr" rid="bibr13-1099800411405031">Cossrow &amp; Falkner, 2004</xref>; <xref ref-type="bibr" rid="bibr27-1099800411405031">Grundy, 1997</xref>). Researchers have shown, however, that African American women have low LDL-cholesterol and high HDL-cholesterol concentrations (<xref ref-type="bibr" rid="bibr13-1099800411405031">Cossrow &amp; Falkner, 2004</xref>; <xref ref-type="bibr" rid="bibr19-1099800411405031">Ferdinand, 2006</xref>) yet still have a higher incidence of CVD (<xref ref-type="bibr" rid="bibr30-1099800411405031">Hendrix, Riehle, &amp; Egan, 2005</xref>).</p>
<p>Cardiovascular disease starts early in the teenage years but often does not manifest until women are in their late 40s or in the perimenopausal years (<xref ref-type="bibr" rid="bibr45-1099800411405031">Nguyen &amp; McLaughlin, 2002</xref>). The Framingham Heart Study (<xref ref-type="bibr" rid="bibr14-1099800411405031">Dawber, Meadors, &amp; Moore, 1951</xref>) was the landmark study that identified the currently accepted risk factors for CVD, which include hypertension, diabetes, hyperlipidemia, advancing age, gender, physical inactivity, obesity, and family history of heart disease (<xref ref-type="bibr" rid="bibr34-1099800411405031">Knopp, 2002</xref>; <xref ref-type="bibr" rid="bibr36-1099800411405031">Li et al., 2008</xref>). Although these traditional risk factors are useful for cardiovascular risk stratification, researchers continue to debate the generalizability of these findings given the homogeneity of the original study sample population. In recent times, researchers have begun exploring obesity’s association with new and novel biomarkers (<xref ref-type="bibr" rid="bibr17-1099800411405031">Eaton, 2005</xref>; <xref ref-type="bibr" rid="bibr20-1099800411405031">Ferns, 2008</xref>; <xref ref-type="bibr" rid="bibr35-1099800411405031">Lastra-Gonzalez, Manrique, Govindarajan, Whaley-Connell, &amp; Sowers, 2005</xref>; <xref ref-type="bibr" rid="bibr48-1099800411405031">Prabhakaran &amp; Anand, 2004</xref>).</p>
<p>There is a growing body of evidence linking atherosclerosis to inflammation (<xref ref-type="bibr" rid="bibr50-1099800411405031">Ross, 1999</xref>; <xref ref-type="bibr" rid="bibr56-1099800411405031">Virani, Polsani, &amp; Nambi, 2008</xref>). Researchers have hypothesized that elevation of markers of inflammation, thrombosis, and endothelial dysfunction (such as high-sensitivity C-reactive protein [hs-CRP], plasminogen activator inhibitor-1 [PAI-1], soluble intercellular adhesion molecule-1 [sICAM-1], E-selectin [eSel], and fibrinogen) predict CVD risk and outcomes in otherwise healthy individuals (<xref ref-type="bibr" rid="bibr37-1099800411405031">Libby, Okamoto, Rocha, &amp; Folco, 2010</xref>; <xref ref-type="bibr" rid="bibr61-1099800411405031">Zebrack &amp; Anderson, 2002</xref>). A clustering of traditional risk factors usually confers higher CVD risk than any one factor alone (<xref ref-type="bibr" rid="bibr47-1099800411405031">Pencina, D’Agostino, Larson, Massaro, &amp; Vasan, 2009</xref>), but it is not clear if these emerging CVD risk factors confer similar synergistic risk. These markers of inflammation, thrombosis, and endothelial dysfunction complement the traditional risk factors. Their utility in clinical practice and relevance for African American women’s CVD risk stratification is under investigation.</p>
<sec id="section1-1099800411405031">
<title>Method</title>
<p>In this pilot study, we utilized a descriptive, correlation research design to examine the association between obesity and traditional and emerging CVD risk factors in adult African American women. We conducted a power analysis based on difference in systolic blood pressure (BP) between groups. Using a two-sided test of significance (α = .05) and a power of 0.80, and assuming a 10 mmHg difference in systolic BP between groups and a standard deviation of 12, we needed a total sample of 48 subjects. We recruited a convenience sample of 50 African American women who met the inclusion criteria. However, two of the women did not complete all study procedures and were excluded from the analysis; thus the final sample was 48 women.</p>
<p>We established the following criteria for eligibility to participate in the study: (a) self-identify as African American woman, (b) 18–45 years of age at the time of enrollment, (c) BMI of 18.5–24.9 kg/m<sup>2</sup> for the normal-weight group or BMI ≥ 30 kg/m<sup>2</sup> for the obese group, (d) ability to read and write English, (e) signed informed consent form prior to participation, and (f) no history of CVD including coronary artery disease (CAD) and cerebrovascular accident (CVA).</p>
<sec id="section2-1099800411405031">
<title>Instruments</title>
<p>Participants independently completed all study questionnaires. <xref ref-type="table" rid="table1-1099800411405031">Table 1</xref>
 provides a summary of the variables and associated measurements.</p>
<table-wrap id="table1-1099800411405031" position="float">
<label>Table 1.</label>
<caption>
<p>Summary of Study Instruments</p>
</caption>
<graphic alternate-form-of="table1-1099800411405031" xlink:href="10.1177_1099800411405031-table1.tif"/>
<table>
<thead>
<tr>
<th>Variable</th>
<th>Measurement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity</td>
<td>Height, weight (BMI)</td>
</tr>
<tr>
<td>Family history of CAD</td>
<td>Self-report (demographic questionnaire)</td>
</tr>
<tr>
<td>Tobacco use</td>
<td>Self-report (demographic questionnaire)</td>
</tr>
<tr>
<td>Physical inactivity</td>
<td>&lt;5 days of moderate physical activity/week—(7-day PAR questionnaire)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Average of two resting blood pressures</td>
</tr>
<tr>
<td>Diabetes, lipid profile (HDL-c, LDL-c, TC, triglyceride)</td>
<td>Fasting blood draws</td>
</tr>
<tr>
<td>Emerging risk factors: hs-CRP, PAI-1, sICAM-1, E-selectin, fibrinogen</td>
<td>Fasting blood draws</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1099800411405031">
<p>
<italic>Note</italic>: 7-day PAR questionnaire = 7-day Physical Activity Recall Questionnaire; BMI = body mass index; CAD = coronary artery disease; HDL-c = high-density lipoprotein cholesterol; hs-CRP = high-sensitivity C-reactive protein; LDL-c = low-density lipoprotein cholesterol; PAI-1 = plasminogen activator inhibitor-1; sICAM-1 = soluble intercellular adhesion molecule-1; TC = total cholesterol.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section3-1099800411405031">
<title>Demographic and health history questionnaire</title>
<p>Participants completed an investigator-developed questionnaire, written at the sixth grade reading level, on health history and issues related to CVD. The multiple-choice questionnaire collected data on various demographic variables including age in years, marital status, educational level classified by degree earned, income level, history of chronic diseases, medication and social history, illicit drug use, amount of alcohol intake, tobacco use, family history of CAD, and history of gastric bypass.</p>
</sec>
<sec id="section5-1099800411405031">
<title>Seven-day physical activity recall (7-day PAR) questionnaire</title>
<p>The 7-day PAR is a self-report recall instrument used to determine the physical activity level of respondents. This questionnaire asks participants to provide detail regarding the intensity, time (duration), and type of physical activity performed during the past 1-week period. It segments the day into three periods—morning, afternoon, and evening—to facilitate recall and groups activity levels as light, moderate, hard, or very hard. These activity categories reflect Ainsworth’s Compendium of Physical Activities, which has 21 categories for major types of physical activities including activities performed at home, during employment, for transportation and, in leisure (<xref ref-type="bibr" rid="bibr1-1099800411405031">Ainsworth et al., 1993</xref>). The compendium assigns metabolic equivalent (MET) values to the different activity levels. A MET is the ratio of the associated metabolic rate for a specific activity divided by the resting metabolic rate, which is approximately 1 MET, and reflects the energy cost of sitting quietly (<xref ref-type="bibr" rid="bibr2-1099800411405031">Ainsworth et al., 2000</xref>). We multiplied time spent in sleep (1 MET), light activities (1.5 METs), moderate activities (3 METs), hard activities (6 METs), and very hard activities (9 METs) by their respective MET values and calculated total kcal of energy expenditure per day (kcal/day) by multiplying total METs by the individual weight in kilograms and dividing by 7 days (<xref ref-type="bibr" rid="bibr2-1099800411405031">Ainsworth et al., 2000</xref>; <xref ref-type="bibr" rid="bibr9-1099800411405031">Blair, 1996</xref>; <xref ref-type="bibr" rid="bibr51-1099800411405031">Sallis et al., 1985</xref>). The validity and reliability of the 7-day PAR within multiethnic adult obese and nonobese populations have been established (<xref ref-type="bibr" rid="bibr53-1099800411405031">Sarkin et al., 1997</xref>). The 7-day PAR correlates with direct measures of physical activity (median <italic>r</italic> = 0.50, <italic>p</italic> &lt; .05) including the gold standard for energy expenditure, doubly labeled water (<italic>r</italic> = 0.58, <italic>p</italic> = .02; <xref ref-type="bibr" rid="bibr57-1099800411405031">Washburn, Jacobsen, Sonko, Hill, &amp; Donnelly, 2003</xref>). The instrument also has adequate test–retest reliability over a 2–4-week period (intraclass correlation coefficients of 0.87; <xref ref-type="bibr" rid="bibr16-1099800411405031">Dubbert, Vander Weg, Kirchner, &amp; Shaw, 2004</xref>).</p>
</sec>
<sec id="section6-1099800411405031">
<title>Blood pressure screening</title>
<p>We measured participants’ BP and heart rate according to the guidelines provided by the Seventh Joint National committee (JNC 7) on the Prevention, Detection, Evaluation, and Treatment of High BP (<xref ref-type="bibr" rid="bibr11-1099800411405031">Chobanian et al., 2003</xref>). The principal investigator (PI) used the auscultatory method of BP measurement with a random zero sphygmomanometer. Participants sat comfortably for 5 min with their back and arm supported, legs uncrossed, and the upper arm at the level of the right atrium before the PI took the first reading. She took two readings 5 min apart on the right arm while the study participant remained seated. The PI used an appropriate-sized cuff with a cuff bladder able to encircle at least 80% of the arm to ensure accuracy of the results. We used the average of the two BP measurements to classify each participant, according to the JNC-7 protocol, as having normal BP (systolic BP &lt; 120 mmHg and diastolic BP &lt; 80 mmHg), prehypertension (systolic BP 120–139 mmHg or diastolic BP 80–89 mmHg), or hypertension (systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg or the use of an antihypertensive agent).</p>
</sec>
<sec id="section7-1099800411405031">
<title>Anthropometric assessment</title>
<p>The same investigators obtained height, weight, waist, and hip measurements from each participant. Participants removed shoes, heavy outer clothing, hats, and barrettes before we obtained their height and weight. We obtained height to the nearest centimeter using a scale-mounted height bar (i.e., stadiometer) and weight to the nearest 10th of a kilogram using a calibrated electronic balance scale. Although we used different weight scales at each of the different locations, we standardized the scales to within 0.05 pounds of each other by using an objective known weight. The investigator used the same tape measure to obtain waist and hip circumferences for all the participants, measuring the waist midway between the bottom of the ribs and the top of the hip bone and the hips at the lowest point between the hips and buttocks in the standing position. We computed waist–hip ratio (WHR) in centimeter as waist divided by hip and BMI by dividing participants’ weight in kilogram by the square of their height in meters. The American Heart Association has set WHR &gt; 0.80 as a criterion to indicate a pattern of central obesity and an increased risk of CVD in women (<xref ref-type="bibr" rid="bibr6-1099800411405031">American Heart Association, 1992</xref>). The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) has proposed a waist circumference (WC) ≥ 88 cm (35 in.) in women as one of the criteria of the metabolic syndrome (<xref ref-type="bibr" rid="bibr43-1099800411405031">NCEP, 1993</xref>).</p>
</sec>
<sec id="section8-1099800411405031">
<title>Blood collection for traditional and emerging risk factors</title>
<p>Following a 10-hr overnight fast, we collected 30 cc of blood from each participant for measurement of glucose, lipid profile, hs-CRP, PAI-1, sICAM-1, eSel, and fibrinogen. We subsequently aliquoted the samples into cryo tubes and stored them in a −80°C freezer until processing. We conducted sample analyses at the University of Miami Diabetes Research Institute and the University of Tennessee Health Science Center. We measured plasma glucose in triplicate using the glucose oxidase method (<xref ref-type="bibr" rid="bibr33-1099800411405031">Kadish &amp; Hall, 1965</xref>). To identify impairment in glucose metabolism, we used the <xref ref-type="bibr" rid="bibr5-1099800411405031">American Diabetes Association (2008)</xref> diagnostic criteria, classifying fasting plasma glucose levels of 100–125 mg/dl as impaired fasting glucose (IFG) and levels ≥126 mg/dl as diabetes mellitus. We measured total and HDL cholesterol and triglyceride levels by spectrophotometry and calculated LDL cholesterol using the Friedewald formula (<xref ref-type="bibr" rid="bibr25-1099800411405031">Friedewald, Levy, &amp; Fredrickson, 1972</xref>). When triglycerides levels are over 400, the established practice is to directly measure rather than calculate LDL, however, none of our participants had levels &gt;400. Normal values for total cholesterol (&gt;200 mg/dl), LDL cholesterol (&gt;130 mg/dl), HDL cholesterol (≤50 mg/dl), and triglyceride levels (&gt;150 mg/dl) are based upon National Cholesterol Education Program criteria (<xref ref-type="bibr" rid="bibr12-1099800411405031">Cleeman &amp; Lenfant, 1998</xref>; <xref ref-type="bibr" rid="bibr18-1099800411405031">Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001</xref>). <xref ref-type="table" rid="table2-1099800411405031">Table 2</xref>
 shows the reference ranges for the dependent variables.</p>
<table-wrap id="table2-1099800411405031" position="float">
<label>Table 2.</label>
<caption>
<p>Reference Ranges for Traditional and Emerging Cardiovascular Disease (CVD) Risk Factors</p>
</caption>
<graphic alternate-form-of="table2-1099800411405031" xlink:href="10.1177_1099800411405031-table2.tif"/>
<table>
<thead>
<tr>
<th>Risk Factors</th>
<th>Reference Ranges</th>
<th>Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTN</td>
<td>SBP ≥ 140 mmHg or DBP ≥ 90 mmHg</td>
<td>
<xref ref-type="bibr" rid="bibr11-1099800411405031">Chobanian et al. (2003)</xref>
</td>
</tr>
<tr>
<td>Pre-HTN</td>
<td>SBP 120–139 mmHg or DBP 80–89 mmHg</td>
<td>
<xref ref-type="bibr" rid="bibr11-1099800411405031">Chobanian et al. (2003)</xref>
</td>
</tr>
<tr>
<td>Diabetes</td>
<td>FPG ≥ 126 mg/dl</td>
<td>
<xref ref-type="bibr" rid="bibr5-1099800411405031">American Diabetes Association (2008)</xref>
</td>
</tr>
<tr>
<td>Prediabetes</td>
<td>FPG 100–125 mg/dl</td>
<td>
<xref ref-type="bibr" rid="bibr5-1099800411405031">American Diabetes Association (2008)</xref>
</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>&gt;200 mg/dl</td>
<td>
<xref ref-type="bibr" rid="bibr12-1099800411405031">Cleeman and Lenfant (1998)</xref>; <xref ref-type="bibr" rid="bibr18-1099800411405031">Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Expert Panel) (2001)</xref>
</td>
</tr>
<tr>
<td>LDL-c</td>
<td>&gt;130 mg/dl</td>
<td>
<xref ref-type="bibr" rid="bibr12-1099800411405031">Cleeman and Lenfant (1998)</xref>; <xref ref-type="bibr" rid="bibr18-1099800411405031">Expert Panel (2001)</xref>
</td>
</tr>
<tr>
<td>HDL-c</td>
<td>≤50 mg/dl</td>
<td>
<xref ref-type="bibr" rid="bibr12-1099800411405031">Cleeman and Lenfant (1998)</xref>; <xref ref-type="bibr" rid="bibr18-1099800411405031">Expert Panel (2001)</xref>
</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>&gt;150 mg/dl</td>
<td>
<xref ref-type="bibr" rid="bibr12-1099800411405031">Cleeman and Lenfant (1998)</xref>; <xref ref-type="bibr" rid="bibr18-1099800411405031">Expert Panel (2001)</xref>
</td>
</tr>
<tr>
<td>Hs-CRP</td>
<td>&gt;2 mg/L</td>
<td>
<xref ref-type="bibr" rid="bibr46-1099800411405031">Pearson et al. (2003)</xref>
</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>&gt;350 mg/dl</td>
<td>University of Miami Diabetes Lab</td>
</tr>
<tr>
<td>PAI-1</td>
<td>21.0 ± 7.2 ng/ml</td>
<td>
<xref ref-type="bibr" rid="bibr38-1099800411405031">LINCO Research (2005)</xref>
</td>
</tr>
<tr>
<td>E-selectin</td>
<td>17.9–79.2 ng/ml</td>
<td>
<xref ref-type="bibr" rid="bibr38-1099800411405031">LINCO Research (2005)</xref>
</td>
</tr>
<tr>
<td>sICAM-1</td>
<td>98.8–320 ng/ml</td>
<td>
<xref ref-type="bibr" rid="bibr38-1099800411405031">LINCO Research (2005)</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1099800411405031">
<p>
<italic>Note</italic>: DBP = diastolic blood pressure; FPG = fasting plasma glucose; HDL-c = high-density lipoprotein cholesterol; HTN = hypertension; Hs-CRP = high-sensitivity C-reactive protein; LDL-c = low-density lipoprotein cholesterol; PAI-1 = plasminogen activator inhibitor-1; Pre-HTN = prehypertension; SBP = systolic blood pressure; sICAM-1 = soluble intercellular adhesion molecule-1.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>We determined serum fibrinogen and hs-CRP levels via a nephelometric method using the Behring Nephelometer 100 Analyzer (Dade Behring). Normal laboratory values for fibrinogen are 200–350 mg/dl. We based our interpretation of hs-CRP results on recommendations presented at a joint American Heart Association/Centers for Disease Control and Prevention workshop for CVD risk classification: &lt;1 mg/L = low risk, 1–3 mg/L = average risk, and &gt; 3 mg/L = high risk (<xref ref-type="bibr" rid="bibr46-1099800411405031">Pearson et al., 2003</xref>).</p>
<p>We performed simultaneous quantification of PAI-1, eSel, and sICAM-1 using the multiplex assay kit (Millipore Corporation, St. Charles, Missouri) on the Luminex xPonent System. We ran the assays on a 96-well plate, in duplicate, on standards, controls, and serum samples. Consistent with manufacturer’s guidelines, we added matrix solution to the background, standards, and control wells and used assay buffer as matrix solution before adding the samples into the appropriate wells. We subsequently added mixed beads, sealed the plates, covered them with aluminum foil and placed them overnight on a plate shaker. We used vacuum filtration to remove the wash buffer before adding streptavidin–phycoerythrin and then placed the plate in a plate shaker for 30 min. We also performed vacuum filtration twice before we finally ran the plate on a Luminex instrument. The following values are used in clinical research for healthy controls: ICAM-1 range is 98.8–320 ng/ml, eSel range is 17.9–79.2 ng/ml, and PAI-1 is 21.0 ± 7.2 ng/ml (<xref ref-type="bibr" rid="bibr38-1099800411405031">LINCO Research, 2005</xref>).</p>
</sec>
</sec>
<sec id="section9-1099800411405031">
<title>Procedure</title>
<p>We obtained Institutional Review Board approval from the University of Tennessee Health Science Center prior to initiation of this study. We recruited participants through flyers and contact with area nurse practitioners in family practice and internal medicine clinics from three geographic regions across two southern states as well as from a university-based facility that transitions women from welfare to work. We conducted screening for age, ethnicity, and history of CVD, CAD, and CVA at the study sites using a standard screening questionnaire and provided instructions on the study protocol. We obtained written informed consent from 50 women who met the inclusion criteria: 14 from Jackson, Mississippi; 15 from Nashville, Tennessee; and 21 from Memphis, Tennessee. Only 48 of the 50 completed the required protocol. We collected data at each site via questionnaires, anthropometric measures, and laboratory results and recorded them in a password-protected Microsoft Excel computer spreadsheet. Data-coding protected participants’ confidentiality and promoted anonymity. Participants received written laboratory results as they became available along with a recommendation to review study results with their primary care providers. After completing study measures, participants received $20 and breakfast.</p>
</sec>
<sec id="section10-1099800411405031">
<title>Data Analysis</title>
<p>We analyzed study data using Statistical Analysis Software (SAS) version 9.1.3 (Cary, North Carolina), characterizing the study sample using measures of central tendency, variability, and frequency distributions. We examined the relationships and degree of association among the variables using Spearman’s ρ correlation coefficients and differences in risk factors between the obese and normal-weight groups using Mann–Whitney Wilcoxon test for continuous variables and chi-square for nominal variables. We set an α level of .05 a priori for statistical significance.</p>
</sec>
</sec>
<sec id="section11-1099800411405031">
<title>Results</title>
<p><xref ref-type="table" rid="table3-1099800411405031">Tables 3</xref> and <xref ref-type="table" rid="table4-1099800411405031">4</xref> display a summary of study sample characteristics and the prevalence of CVD risk factors, respectively. The most common traditional CVD risk factor among study participants was physical inactivity (<italic>n</italic> = 35, 72.9%). More than half of the participants reported a positive family history of CVD, defined as history of myocardial infarction, CAD, congestive heart failure or CVA in a first-degree relative or grandparent. Obesity was equally prevalent in our study population. Likewise, more than half (27 [56.3%]) of our participants had a WC &gt;88 cm, and 37 (77.1%) had a WHR &gt;0.80. Out of all the subjects that had a WC &gt;88 cm, 23 (47.9%) were obese, while 4 (8.3%) were normal weight. Out of the participants who had a WHR &gt;0.80, 23 (47.9%) were obese and 14 (29.2%) were normal weight. Though 25% of women reported current use of tobacco, we elicited neither the amount nor route of use. Hypertension and diabetes were the least prevalent risk factors, with each affecting less than 5% of the participants.</p>
<table-wrap id="table3-1099800411405031" position="float">
<label>Table 3.</label>
<caption>
<p>Characteristics of Study Participants (N = 48)</p>
</caption>
<graphic alternate-form-of="table3-1099800411405031" xlink:href="10.1177_1099800411405031-table3.tif"/>
<table>
<thead>
<tr>
<th>Variable</th>
<th align="center">
<italic>n</italic> (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marital status</td>
<td>
</td>
</tr>
<tr>
<td> Single</td>
<td>35 (72.9</td>
</tr>
<tr>
<td> Married</td>
<td>13 (27.1)</td>
</tr>
<tr>
<td>Educational level completed</td>
<td>
</td>
</tr>
<tr>
<td> College</td>
<td>31 (64.6)</td>
</tr>
<tr>
<td> High school</td>
<td>17 (35.4)</td>
</tr>
<tr>
<td>Household income</td>
<td>
</td>
</tr>
<tr>
<td> &lt;$25,000</td>
<td>20 (41.7)</td>
</tr>
<tr>
<td> $25–$50,000</td>
<td>16 (33.3)</td>
</tr>
<tr>
<td> &gt;$50,000</td>
<td>12 (25.0)</td>
</tr>
<tr>
<td>Employment status</td>
<td>
</td>
</tr>
<tr>
<td> Employed</td>
<td>30 (62.5)</td>
</tr>
<tr>
<td> Unemployed</td>
<td>18 (37.5)</td>
</tr>
<tr>
<td>Illicit drug use</td>
<td>
</td>
</tr>
<tr>
<td> Marijuana</td>
<td>5 (10.4%)</td>
</tr>
<tr>
<td> Cocaine</td>
<td>0</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table4-1099800411405031" position="float">
<label>Table 4.</label>
<caption>
<p>Prevalence of Traditional and Emerging Cardiovascular Disease (CVD) Risk Factors Among Participants</p>
</caption>
<graphic alternate-form-of="table4-1099800411405031" xlink:href="10.1177_1099800411405031-table4.tif"/>
<table>
<thead>
<tr>
<th>(CVD) Risk Factors</th>
<th>Prevalence Rates, <italic>n</italic> (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>2 (4.2)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>2 (4.2)</td>
</tr>
<tr>
<td>sICAM-1<sup><xref ref-type="table-fn" rid="table-fn4-1099800411405031">b</xref></sup>
</td>
<td>2 (7.4)</td>
</tr>
<tr>
<td>E-selectin<sup><xref ref-type="table-fn" rid="table-fn4-1099800411405031">b</xref></sup>
</td>
<td>3 (6.2)</td>
</tr>
<tr>
<td>Elevated triglycerides</td>
<td>3 (6.3)</td>
</tr>
<tr>
<td>LDL-c</td>
<td>8 (16.7)</td>
</tr>
<tr>
<td>Elevated total cholesterol</td>
<td>9 (18.8)</td>
</tr>
<tr>
<td>Tobacco use</td>
<td>12 (25)</td>
</tr>
<tr>
<td>HDL-c</td>
<td>18 (37.5)</td>
</tr>
<tr>
<td>hs-CRP</td>
<td>22 (45.8)</td>
</tr>
<tr>
<td>PAI-1<sup><xref ref-type="table-fn" rid="table-fn5-1099800411405031">b</xref></sup>
</td>
<td>22 (45.8)</td>
</tr>
<tr>
<td>Fibrinogen<sup><xref ref-type="table-fn" rid="table-fn6-1099800411405031">c</xref></sup>
</td>
<td>27 (56.3)</td>
</tr>
<tr>
<td>Obesity</td>
<td>27 (56.3)</td>
</tr>
<tr>
<td>Family history of CVD</td>
<td>28 (58.3)</td>
</tr>
<tr>
<td>Physical inactivity<sup><xref ref-type="table-fn" rid="table-fn4-1099800411405031">a</xref>
</sup>
</td>
<td>35 (72.92)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1099800411405031">
<p>
<italic>Note</italic>: HDL-c = high density lipoprotein cholesterol; hs-CRP = high-sensitivity C-reactive protein; LDL-c = low-density lipoprotein cholesterol; PAI-1 = plasminogen activator inhibitor-1; sICAM-1 = soluble intercellular adhesion molecule-1.</p>
</fn>
<fn id="table-fn4-1099800411405031">
<p>
<sup>a</sup> We defined physical inactivity as &lt;5 days of moderate physical activity/week.</p>
</fn>
<fn id="table-fn5-1099800411405031">
<p>
<sup>b</sup> Indicates that the norms for these emerging risk factors are not yet established. Values used to represent a risk factor are from reported research data.</p>
</fn>
<fn id="table-fn6-1099800411405031">
<p>
<sup>c</sup>
<italic>n</italic> = 47 due to technical difficulties.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Emerging CVD risk factors were also prevalent in our participants. Almost half of the women had elevated hs-CRP (≥3 mg/dl) and PAI-1 (&gt;28.2 ng/ml) levels, while just over half had an abnormal fibrinogen (&gt;350 mg/dl) level. The eSel (&gt;79.2 ng/ml) and sICAM levels were elevated in just under and just over 5% of participants, respectively. Although normative values have not been determined for PAI-1, e-Sel, and sICAM-1, the cut points we used to classify participants as having the risk factor reflect values reported in published research (<xref ref-type="bibr" rid="bibr38-1099800411405031">LINCO Research, 2005</xref>). In the absence of standardized cut points for these biomarkers, the utility of study findings for clinical practice is unclear. Fibrinogen and hs-CRP, however, are clinically available cardiac biomarkers with established normative values.</p>
<p>We further compared the median values of traditional and emerging CVD risk factors between the normal-weight and obese groups using the Mann–Whitney <italic>U</italic> test (<xref ref-type="table" rid="table5-1099800411405031">Table 5</xref>
). The obese group had significantly higher systolic and diastolic BP. We also noted significantly higher triglyceride, hs-CRP, and fibrinogen levels among the obese compared to the normal-weight group. The obese group had a lower HDL-c level compared to the normal-weight group.</p>
<table-wrap id="table5-1099800411405031" position="float">
<label>Table 5.</label>
<caption>
<p>Median Values of Traditional and Emerging Cardiovascular Disease (CVD) Risk Factors Among Normal and Obese Weight Groups</p>
</caption>
<graphic alternate-form-of="table5-1099800411405031" xlink:href="10.1177_1099800411405031-table5.tif"/>
<table>
<thead>
<tr>
<th>Risk Factors</th>
<th>Normal Weight, (<italic>n</italic> = 21), <italic>M</italic> (IQR)</th>
<th>Obese, (<italic>n</italic> = 27), <italic>M</italic> (IQR)</th>
<th>
<italic>p</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASBP (mmHg)</td>
<td>103.5 (99.5, 110)</td>
<td>120.5 (115, 128.5)</td>
<td>.0002</td>
</tr>
<tr>
<td>ADBP (mmHg)</td>
<td>67.5 (63, 72)</td>
<td>74.5 (70, 80)</td>
<td>.0007</td>
</tr>
<tr>
<td>HDL-c (mg/dl)</td>
<td>58 (52, 65)</td>
<td>49 (38, 57)</td>
<td>.01</td>
</tr>
<tr>
<td>Triglyceride (mg/dl)</td>
<td>56 (52, 66)</td>
<td>71 (59, 97)</td>
<td>.02</td>
</tr>
<tr>
<td>Hs-CRP (mg/L)</td>
<td>0.7 (0.3, 2.0)</td>
<td>4.1 (1.3, 10.4)</td>
<td>.002</td>
</tr>
<tr>
<td>Fibrinogen (mg/dl)</td>
<td>332 (296, 388)</td>
<td>441 (354.5, 481)</td>
<td>.01</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1099800411405031">
<p>
<italic>Note</italic>: ADBP = average diastolic blood pressure; ASBP = average systolic blood pressure; HDL-c = high-density lipoprotein cholesterol; hs-CRP = high-sensitivity C-reactive protein; IQR = interquartile range; <italic>M</italic> = median.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>We also examined the median number of risk factors an individual participant had by summing the number of risk factors and dividing by the sample population. The average number of risk factors was 5.7 for the sample as a whole. However, the obese group had significantly more risk factors compared to the normal-weight group (median 6 vs. 4, <italic>p</italic> &lt; .0001).</p>
<p>Furthermore, we determined the average number of risk factors based on physical activity status by weight group and compared the groups. We determined the total number of risk factors within each weight category and divided by the total score for the group’s physical activity category. The obese participants who were physically active had an average of 6.6 risk factors compared to 6.9 for the inactive obese participants (<italic>p</italic> = .72). Similarly, the normal-weight participants who were active had an average of 3.9 risk factors compared to 4.3 in those who were physically inactive (<italic>p</italic> = .58). While there were no statistically significant differences within weight groups, we noted a statistically significant difference between weight groups at similar activity levels. The active obese weight group had significantly more risk factors than the active normal-weight group (6.6 vs. 3.9 risk factors, <italic>p</italic> = .009) as did the inactive obese weight group compared to the inactive normal-weight group (6.9 vs. 4.3 risk factors, <italic>p</italic> = .001).</p>
</sec>
<sec id="section12-1099800411405031">
<title>Discussion</title>
<p>The results of this study show that both the traditional and emerging CVD risk factors were more prevalent among the obese compared with the normal-weight subjects. This difference was statistically significant with regard to average systolic BP (<italic>p</italic> = .0002), average diastolic BP (<italic>p</italic> = .0007), triglycerides (<italic>p</italic> = .02), HDL-c (<italic>p</italic> = .02), hs-CRP (<italic>p</italic> = .01), and fibrinogen (<italic>p</italic> = .002). These findings are similar to the results of the Multi-Ethnic Study of Atherosclerosis, which examined the relationship of obesity to traditional risk factors in individuals 45–84-years-old (<xref ref-type="bibr" rid="bibr8-1099800411405031">Bild et al., 2005</xref>). Other studies have similarly shown a higher prevalence of emerging cardiovascular risk factors among obese young adults (<xref ref-type="bibr" rid="bibr7-1099800411405031">Appel, Harrell, &amp; Davenport, 2005</xref>; <xref ref-type="bibr" rid="bibr52-1099800411405031">Santos, Lopes, Guimaraes, &amp; Barros, 2005</xref>).</p>
<p>The metabolic syndrome is characterized as a clustering of risk factors including abdominal obesity, atherogenic dyslipidemia, elevated BP, insulin resistance, and glucose intolerance (<xref ref-type="bibr" rid="bibr28-1099800411405031">Grundy et al., 2004</xref>). Researchers have reported central adiposity to be more strongly associated with metabolic and cardiovascular problems than total adiposity. For instance, in the INTERHEART Study, a multicountry group of investigators compared 12,461 cases of first heart attack with 14,637 controls from all major geographic areas of the world in regard to BMI, WC, hip circumference, and WHR and reported that obesity is not nearly as informative as WHR (<xref ref-type="bibr" rid="bibr60-1099800411405031">Yusuf et al., 2005</xref>). These findings carry implications for clinical practice. Obese adults without clinical CVD may already have a clustering of both traditional and emerging CVD risk factors. Institution of early and aggressive preventive measures in this population could delay or arrest progression to clinical CVD.</p>
<p>Contrary to previous studies that reported a higher prevalence of diabetes and hypertension among African American women (<xref ref-type="bibr" rid="bibr24-1099800411405031">Ford, Li, Zhao, Pearson, &amp; Capewell, 2009</xref>; <xref ref-type="bibr" rid="bibr39-1099800411405031">Link &amp; McKinlay, 2009</xref>; <xref ref-type="bibr" rid="bibr49-1099800411405031">Razzouk &amp; Muntner, 2009</xref>), hypertension and diabetes were the least prevalent (4.2%) among our study population of all the traditional risk factors. This result could reflect the fact that the participants were young and relatively healthy except for the presence of obesity. The Centers for Disease Control and Prevention analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS) for the period 1994–2004 and reported that non-Hispanic Black women had a prevalence rate of 33.9% in leisure time physical inactivity, while our study showed a 72.9% self-reported physical inactivity prevalence rate.</p>
<p>Investigators do not routinely report prevalence rates of the emerging CVD risk factors in the literature. This is not surprising given the newness of most of these biomarkers and the lack of large studies to determine normative values. Reference ranges reported in the literature may vary depending on the methodology used for the respective tests. Our previously published study highlighted the limited use of these novel markers in clinical practice (<xref ref-type="bibr" rid="bibr31-1099800411405031">Henry-Okafor, Cowan, Zhao, &amp; Khoo, 2009</xref>). However, available literature indicates that biomarkers such as hs-CRP, fibrinogen, PAI-1, eSel, and sICAM-1 vary in their levels among people of diverse ethnic identities, particularly in African Americans relative to other groups (<xref ref-type="bibr" rid="bibr4-1099800411405031">Albert &amp; Ridker, 2006</xref>; <xref ref-type="bibr" rid="bibr54-1099800411405031">Sumner et al., 2008</xref>). The significance of our study findings lies in the fact that these emerging CVD risk factors were prevalent in healthy, young African American women and may be indicative of preclinical CVD. Early detection of these risk markers for CVD could enhance the development of diagnostic and therapeutic interventions that could prevent progression of the disease in later years.</p>
<p>Cardiovascular risk and outcomes are also affected by sociocultural factors. More of the participants in the obese group reported having a high school education or lower and earned less annual household income compared to the normal-weight group. Even though we did not evaluate health belief systems or health-seeking behaviors, we ascertained that all the study participants had health insurance coverage. Researchers have found socioeconomic status to be a limiting factor in access to health care as well as the quality of care received (<xref ref-type="bibr" rid="bibr26-1099800411405031">Griffith, Moy, Reischl, &amp; Dayton, 2006</xref>). While this may be true in many studies, it was not so in the current study, as all subjects had health insurance. Some investigators have suggested that an individual’s genetic profile is more important than obesity in the evaluation of endothelial dysfunction markers, an assertion that needs further exploration in this population (<xref ref-type="bibr" rid="bibr10-1099800411405031">Caballero, 2003</xref>; <xref ref-type="bibr" rid="bibr59-1099800411405031">Yudkin, Stehouwer, Emeis, &amp; Coppack, 1999</xref>).</p>
</sec>
<sec id="section13-1099800411405031">
<title>Limitations</title>
<p>A cross-sectional design allows researchers to gather data from one point in time, which may not reflect the totality of the participants’ experiences. Hence, the findings of this study, though valid, may not necessarily represent the influence of body weight on CVD risk factors over time. A longitudinal research study might be a better approach for assessing the long-term relationship between body weight and CVD risk factors. Another inherent limitation to this study is the small sample size and lack of regional and cultural diversity. Participants resided in two adjoining states in the mid-South, an area with high-obesity prevalence. Our findings may not be characteristic of other African American women from other parts of the country. The use of self-report instruments to elicit information regarding illicit drug and daily physical activity levels is another limitation due to potential recall bias and underreporting. In addition, given the multitude of measures we assessed in this pilot study, we elected to omit measuring dietary intake in order to minimize subjects’ burden. Another limitation of this study was our decision to exclude the overweight group (BMI of 25–29.9 kg/m<sup>2</sup>). Using the two extreme groups maximized between-group variance so that we could better detect group differences in the emerging biomarkers. However, because we did not examine overweight individuals we cannot evaluate whether differences in risk factors might be apparent earlier in the weight continuum. Inclusion of women across the weight continuum would have allowed us to investigate the incremental effect of weight on the CVD risk factors. Given that the focus of the study was to describe the relationship between BMI and traditional and emerging CVD risk factors, we did not exclude subjects with risk factors, such as diabetes, hypertension, tobacco use, and dyslipidemia. Lastly, several of the emerging CVD risk factors are by definition novel and, therefore, have no established cut points.</p>
</sec>
<sec id="section14-1099800411405031">
<title>Relevance to Nursing Practice and Research</title>
<p>We found that the CVD risk factors that often occur with obesity were prevalent in both the normal-weight and the obese groups of the study sample. There were no statistically significant differences between obese and nonobese women for several cardiovascular risk factors, including LDL-c, total cholesterol, physical inactivity, smoking, hypertension, PAI-1, eSel, and sICAM-1. This finding suggests that there could be other indicators for cardiovascular risk beyond BMI, such as psychosocial and genetic determinants of health and well-being, which were beyond the scope of this study. However, a greater number of risks did occur in the presence of obesity.</p>
<p>Health care providers should engage in widespread CVD -prevention education programs that are culturally relevant. A collaborative effort between health care professionals and members of minority communities is necessary to achieve effective outcomes that increase physical activity in this population. Nurses and other providers should encourage African American women, like other people, to seek regular medical evaluation with detailed screening for risk factors, even when asymptomatic, as this may represent the best opportunity to limit the devastating effects of CVD. Institution of early and preventive measures in this population could delay or arrest progression to clinical CVD.</p>
<p>While participants in this study had access to health care because all had health insurance, many African American women do not, and coverage for preventive health and health promotion services are often limited. African American women who are uninsured and underinsured need access to care, health promotion information, and other resources to increase awareness of the importance of CVD risk prevention and management. Without these resources, disparities in cardiovascular outcomes will likely persist in African American women.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors acknowledge the dissertation year fellowship award support provided by the Southern Regional Education Board (SREB) and the College of Nursing and College of Graduate Health Sciences, University of Tennessee Health Science Center for assisting with laboratory costs and for travel support to present research findings.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-1099800411405031">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<fn-group>
<fn fn-type="financial-disclosure" id="fn2-1099800411405031">
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ainsworth</surname>
<given-names>B. E.</given-names>
</name>
<name>
<surname>Haskell</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Leon</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>D. R.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Montoye</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Sallis</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Paffenbarger</surname>
<given-names>R. S.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group> (<year>1993</year>). <article-title>Compendium of physical activities: Classification of energy costs of human physical activities</article-title>. <source>Medicine and Science in Sports and Exercise</source>, <volume>25</volume>, <fpage>71</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr2-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ainsworth</surname>
<given-names>B. E.</given-names>
</name>
<name>
<surname>Haskell</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Whitt</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Swartz</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Strath</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>, … Leon</surname>
<given-names>A. S.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Compendium of physical activities: An update of activity codes and MET intensities</article-title>. <source>Medicine and Science in Sports and Exercise</source>, <volume>32</volume>(<issue>Suppl. 9</issue>):<fpage>S498</fpage>–<lpage>504</lpage>.</citation>
</ref>
<ref id="bibr3-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alagona</surname>
<given-names>P.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group> (<year>2009</year>). <article-title>Beyond LDL cholesterol: The role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy</article-title>. <source>American Journal of Managed Care</source>, <volume>15</volume>(<issue>Suppl. 3</issue>):<fpage>S65</fpage>–<lpage>S73</lpage>.</citation>
</ref>
<ref id="bibr4-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albert</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Ridker</surname>
<given-names>P. M.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>C-reactive protein as a risk predictor: Do race/ethnicity and gender make a difference?</article-title> <source>Circulation</source>, <volume>114</volume>, <fpage>e67</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr5-1099800411405031">
<citation citation-type="book">
<collab collab-type="author">American Diabetes Association</collab>. (<year>2008</year>). <source>Medical management of type 2 diabetes</source> (<edition>6th ed</edition>). <publisher-loc>Alexandria, VA</publisher-loc>: <publisher-name>Author</publisher-name>.</citation>
</ref>
<ref id="bibr6-1099800411405031">
<citation citation-type="web">
<collab collab-type="author">American Heart Association</collab>. (<year>1992</year>). <source>Heart and stroke facts</source>. <comment>Dallas, TX: Author. Retrieved from</comment> <ext-link ext-link-type="uri" xlink:href="http://www.americanheart.org/presenter.jhtml?identifier=3000333">http://www.americanheart.org/presenter.jhtml?identifier=3000333</ext-link></citation>
</ref>
<ref id="bibr7-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Appel</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Harrell</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Davenport</surname>
<given-names>M. L.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults</article-title>. <source>Journal of the American Academy of Nurse Practitioners</source>, <volume>17</volume>, <fpage>535</fpage>–<lpage>541</lpage>.</citation>
</ref>
<ref id="bibr8-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bild</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Detrano</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Guerci</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shahar</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>, … Saad</surname>
<given-names>M. F.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Ethnic differences in coronary calcification: The Multi-Ethnic Study of Atherosclerosis (MESA)</article-title>. <source>Circulation</source>, <volume>111</volume>, <fpage>1313</fpage>–<lpage>1320</lpage>.</citation>
</ref>
<ref id="bibr9-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blair</surname>
<given-names>S. N.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Physical inactivity and cardiovascular disease risk in women</article-title>. <source>Medicine and Science in Sports and Exercise</source>, <volume>28</volume>, <fpage>9</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr10-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caballero</surname>
<given-names>A. E.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Endothelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease</article-title>. <source>Obesity Research</source>, <volume>11</volume>, <fpage>1278</fpage>–<lpage>1289</lpage>.</citation>
</ref>
<ref id="bibr11-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chobanian</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Bakris</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>H. R.</given-names>
</name>
<name>
<surname>Cushman</surname>
<given-names>W. C.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Izzo</surname>
<given-names>J. L.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>, … Roccella</surname>
<given-names>E. J.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report</article-title>. <source>Journal of the American Medical Association</source>, <volume>289</volume>, <fpage>2560</fpage>–<lpage>2572</lpage>.</citation>
</ref>
<ref id="bibr12-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cleeman</surname>
<given-names>J. I.</given-names>
</name>
<name>
<surname>Lenfant</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>The National Cholesterol Education Program: Progress and prospects</article-title>. <source>Journal of the American Medical Association</source>, <volume>280</volume>, <fpage>2099</fpage>–<lpage>2104</lpage>.</citation>
</ref>
<ref id="bibr13-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cossrow</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Falkner</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Race/ethnic issues in obesity and obesity-related comorbidities</article-title>. <source>Journal of Clinical Endocrinology and Metabolism</source>, <volume>89</volume>, <fpage>2590</fpage>–<lpage>2594</lpage>.</citation>
</ref>
<ref id="bibr14-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dawber</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Meadors</surname>
<given-names>G. F.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>F. E.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group> (<year>1951</year>). <article-title>Epidemiological approaches to heart disease: The Framingham Study</article-title>. <source>American Journal of Public Health and the Nations Health</source>, <volume>41</volume>, <fpage>279</fpage>–<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr15-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Despres</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Arsenault</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Cote</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cartier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lemieux</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Abdominal obesity: The cholesterol of the 21st century?</article-title> <source>Canadian Journal of Cardiology</source>, <volume>24</volume>(<issue>Suppl. D</issue>):<fpage>7D</fpage>–<lpage>12D</lpage>.</citation>
</ref>
<ref id="bibr16-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubbert</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Vander Weg</surname>
<given-names>M. W.</given-names>
</name>
<name>
<surname>Kirchner</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Evaluation of the 7-day physical activity recall in urban and rural men</article-title>. <source>Medicine and Science in Sports and Exercise</source>, <volume>36</volume>, <fpage>1646</fpage>–<lpage>1654</lpage>.</citation>
</ref>
<ref id="bibr17-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eaton</surname>
<given-names>C. B.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Traditional and emerging risk factors for cardiovascular disease</article-title>. <source>Primary Care; Clinics in Office Practice</source>, <volume>32</volume>, <fpage>963</fpage>–<lpage>976</lpage>., <comment>vii</comment>.</citation>
</ref>
<ref id="bibr18-1099800411405031">
<citation citation-type="journal">
<collab collab-type="author">Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults</collab>. (<year>2001</year>). <article-title>Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)</article-title>. <source>Journal of the American Medical Association</source>, <volume>285</volume>, <fpage>2486</fpage>–<lpage>2497</lpage>.</citation>
</ref>
<ref id="bibr19-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferdinand</surname>
<given-names>K. C.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Ethnic, gender, and age-related differences in the treatment of dyslipidemia</article-title>. <source>American Journal of Managed Care</source>, <volume>12</volume>(<issue>Suppl. 15</issue>):<fpage>S400</fpage>–<lpage>S404</lpage>.</citation>
</ref>
<ref id="bibr20-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferns</surname>
<given-names>G. A.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>New and emerging risk factors for CVD</article-title>. <source>Proceedings of the Nutrition Society</source>, <volume>67</volume>, <fpage>223</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr21-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flegal</surname>
<given-names>K. M.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Obesity, overweight, hypertension, and high blood cholesterol: The importance of age</article-title>. <source>Obesity Research</source>, <volume>8</volume>, <fpage>676</fpage>–<lpage>677</lpage>.</citation>
</ref>
<ref id="bibr22-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flegal</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Kuczmarski</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>C. L.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Overweight and obesity in the United States: Prevalence and trends, 1960–1994</article-title>. <source>International Journal of Obesity and Related Metabolic Disorders</source>, <volume>22</volume>, <fpage>39</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr23-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flegal</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Ogden</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>C. L.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Prevalence and trends in obesity among US adults, 1999–2000</article-title>. <source>Journal of the American Medical Association</source>, <volume>288</volume>, <fpage>1723</fpage>–<lpage>1727</lpage>.</citation>
</ref>
<ref id="bibr24-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ford</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pearson</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Capewell</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Trends in the prevalence of low risk factor burden for cardiovascular disease among United States adults</article-title>. <source>Circulation</source>, <volume>120</volume>, <fpage>1181</fpage>–<lpage>1188</lpage>.</citation>
</ref>
<ref id="bibr25-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedewald</surname>
<given-names>W. T.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>R. I.</given-names>
</name>
<name>
<surname>Fredrickson</surname>
<given-names>D. S.</given-names>
</name>
</person-group> (<year>1972</year>). <article-title>Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge</article-title>. <source>Clinical Chemistry</source>, <volume>18</volume>, <fpage>499</fpage>–<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr26-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griffith</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Moy</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Reischl</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Dayton</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>National data for monitoring and evaluating racial and ethnic health inequities: Where do we go from here?</article-title> <source>Health Education and Behavior</source>, <volume>33</volume>, <fpage>470</fpage>–<lpage>487</lpage>.</citation>
</ref>
<ref id="bibr27-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grundy</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Small LDL, atherogenic dyslipidemia, and the metabolic syndrome</article-title>. <source>Circulation</source>, <volume>95</volume>, <fpage>1</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr28-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grundy</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>S. C.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Cleeman</surname>
<given-names>J. I.</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management</article-title>. <source>Circulation</source>, <volume>109</volume>, <fpage>551</fpage>–<lpage>556</lpage>.</citation>
</ref>
<ref id="bibr29-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hedley</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Ogden</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Curtin</surname>
<given-names>L. R.</given-names>
</name>
<name>
<surname>Flegal</surname>
<given-names>K. M.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002</article-title>. <source>Journal of the American Medical Association</source>, <volume>291</volume>, <fpage>2847</fpage>–<lpage>2850</lpage>.</citation>
</ref>
<ref id="bibr30-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hendrix</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Riehle</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Egan</surname>
<given-names>B. M.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Ethnic, gender, and age-related differences in treatment and control of dyslipidemia in hypertensive patients</article-title>. <source>Ethnicity and Disease</source>, <volume>15</volume>, <fpage>11</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr31-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henry-Okafor</surname>
<given-names>Q. O.</given-names>
</name>
<name>
<surname>Cowan</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>D. X. M.</given-names>
</name>
<name>
<surname>Khoo</surname>
<given-names>M. S. C.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Racial differences in cardiac risk profiles in women undergoing cardiac catheterization</article-title>. <source>American Journal for Nurse Practitioners</source>, <volume>13</volume>, <fpage>49</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr32-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>J. O.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Environmental contributions to the obesity epidemic</article-title>. <source>Science</source>, <volume>280</volume>, <fpage>1371</fpage>–<lpage>1374</lpage>.</citation>
</ref>
<ref id="bibr33-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kadish</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>1965</year>). <article-title>A new method for the continuous monitoring of blood glucose by measurement of dissolved oxygen</article-title>. <source>Clinical Chemistry</source>, <volume>11</volume>, <fpage>869</fpage>–<lpage>875</lpage>.</citation>
</ref>
<ref id="bibr34-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knopp</surname>
<given-names>R. H.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Risk factors for coronary artery disease in women</article-title>. <source>American Journal of Cardiology</source>, <volume>89</volume>, <fpage>28E</fpage>–<lpage>34E</lpage>.; <comment>discussion 34E–35E</comment>.</citation>
</ref>
<ref id="bibr35-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lastra-Gonzalez</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Manrique</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Govindarajan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Whaley-Connell</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sowers</surname>
<given-names>J. R.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Insights into the emerging cardiometabolic prevention and management of diabetes mellitus</article-title>. <source>Expert Opinion on Pharmacotherapy</source>, <volume>6</volume>, <fpage>2209</fpage>–<lpage>2221</lpage>.</citation>
</ref>
<ref id="bibr36-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Mokdad</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Balluz</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Giles</surname>
<given-names>W. H.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Clustering of cardiovascular disease risk factors and health-related quality of life among US adults</article-title>. <source>Value Health</source>, <volume>11</volume>, <fpage>689</fpage>–<lpage>699</lpage>.</citation>
</ref>
<ref id="bibr37-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Libby</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Rocha</surname>
<given-names>V. Z.</given-names>
</name>
<name>
<surname>Folco</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Inflammation in atherosclerosis: Transition from theory to practice</article-title>. <source>Circulation Journal</source>, <volume>74</volume>, <fpage>213</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr38-1099800411405031">
<citation citation-type="book">
<collab collab-type="author">LINCO Research</collab>. (<year>2005</year>). <source>Human cardiovascular disease panel 1 LINCOplex kit (Catalog HCVD1-67AK)</source>
<publisher-loc>St. Charles, MO</publisher-loc>: <publisher-name>Millipore</publisher-name>.</citation>
</ref>
<ref id="bibr39-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Link</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>McKinlay</surname>
<given-names>J. B.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Disparities in the prevalence of diabetes: Is it race/ethnicity or socioeconomic status? Results from the Boston Area Community Health (BACH) Survey</article-title>. <source>Ethnicity &amp; Disease</source>, <volume>19</volume>, <fpage>288</fpage>–<lpage>292</lpage>.</citation>
</ref>
<ref id="bibr40-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mello</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Studdert</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Brennan</surname>
<given-names>T. A.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Obesity—The new frontier of public health law</article-title>. <source>New England Journal of Medicine</source>, <volume>354</volume>, <fpage>2601</fpage>–<lpage>2610</lpage>.</citation>
</ref>
<ref id="bibr41-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mensah</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Mokdad</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Narayan</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Giles</surname>
<given-names>W. H.</given-names>
</name>
<name>
<surname>Vinicor</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Deedwania</surname>
<given-names>P. C.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Obesity, metabolic syndrome, and type 2 diabetes: Emerging epidemics and their cardiovascular implications</article-title>. <source>Cardiology Clinics</source>, <volume>22</volume>, <fpage>485</fpage>–<lpage>504</lpage>.</citation>
</ref>
<ref id="bibr42-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mokdad</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Bowman</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Dietz</surname>
<given-names>W. H.</given-names>
</name>
<name>
<surname>Vinicor</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bales</surname>
<given-names>V. S.</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>J. S.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001</article-title>. <source>Journal of the American Medical Association</source>, <volume>289</volume>, <fpage>76</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr43-1099800411405031">
<citation citation-type="book">
<collab collab-type="author">National Cholesterol Education Program</collab> (<year>1993</year>). <source>Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III)</source>. <comment>NIH publication no. 93-3095</comment>. <publisher-loc>Bethesda, MD</publisher-loc>: <publisher-name>National Heart, Lung, and Blood Institute</publisher-name>.</citation>
</ref>
<ref id="bibr44-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelson</surname>
<given-names>T. L.</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Rosamond</surname>
<given-names>W. D.</given-names>
</name>
<name>
<surname>Ammerman</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Keyserling</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Mokdad</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Will</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Obesity and associated coronary heart disease risk factors in a population of low-income African-American and White women: The North Carolina WISEWOMAN project</article-title>. <source>Preventive Medicine</source>, <volume>35</volume>, <fpage>1</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr45-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>V. H.</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Coronary artery disease in women: A review of emerging cardiovascular risk factors</article-title>. <source>Mount Sinai Journal of Medicine</source>, <volume>69</volume>, <fpage>338</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr46-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pearson</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Mensah</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>R. W.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>R. O. III, Criqui, M.</given-names>
</name>
<name>
<surname>, … Vinicor</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association</article-title>. <source>Circulation</source>, <volume>107</volume>, <fpage>499</fpage>–<lpage>511</lpage>.</citation>
</ref>
<ref id="bibr47-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pencina</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>D’Agostino</surname>
<given-names>R. B.</given-names>
<suffix>Sr.</suffix>
</name>
<name>
<surname>Larson</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Massaro</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Vasan</surname>
<given-names>R. S.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Predicting the 30-year risk of cardiovascular disease: The Framingham Heart Study</article-title>. <source>Circulation</source>, <volume>119</volume>, <fpage>3078</fpage>–<lpage>3084</lpage>.</citation>
</ref>
<ref id="bibr48-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prabhakaran</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Anand</surname>
<given-names>S. S.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>The metabolic syndrome: An emerging risk state for cardiovascular disease</article-title>. <source>Vascular Medicine</source>, <volume>9</volume>, <fpage>55</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr49-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Razzouk</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Muntner</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Ethnic, gender, and age-related differences in patients with the metabolic syndrome</article-title>. <source>Current Hypertension Reports</source>, <volume>11</volume>, <fpage>127</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr50-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Atherosclerosis—An inflammatory disease</article-title>. <source>New England Journal of Medicine</source>, <volume>340</volume>, <fpage>115</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr51-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sallis</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Haskell</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Fortmann</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>S. N.</given-names>
</name>
<name>
<surname>Paffenbarger</surname>
<given-names>R. S.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group> (<year>1985</year>). <article-title>Physical activity assessment methodology in the Five-City Project</article-title>. <source>American Journal of Epidemiology</source>, <volume>121</volume>, <fpage>91</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr52-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santos</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Lopes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guimaraes</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Barros</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome</article-title>. <source>International Journal of Obesity (London)</source>, <volume>29</volume>, <fpage>1452</fpage>–<lpage>1456</lpage>.</citation>
</ref>
<ref id="bibr53-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarkin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Roby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bazzo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sallis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Calfas</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Project GRAD Seven-Day Physical Activity Recall Interviewer’s manual</article-title>. <source>Medicine and Science in Sports and Exercise</source>, <volume>29</volume>(<issue>Suppl</issue>.):<fpage>S91</fpage>–<lpage>S102</lpage>.</citation>
</ref>
<ref id="bibr54-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sumner</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Sen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ricks</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Frempong</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Sebring</surname>
<given-names>N. G.</given-names>
</name>
<name>
<surname>Kushner</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Determining the waist circumference in African Americans which best predicts insulin resistance</article-title>. <source>Obesity</source>, <volume>16</volume>, <fpage>841</fpage>–<lpage>846</lpage>.</citation>
</ref>
<ref id="bibr55-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>H. A.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Coady</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>E. R.</given-names>
</name>
<name>
<surname>Vasan</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>, … Fox</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Relationships of BMI to cardiovascular risk factors differ by ethnicity</article-title>. <source>Obesity</source>, <volume>18</volume>, <fpage>1638</fpage>–<lpage>1645</lpage>.</citation>
</ref>
<ref id="bibr56-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Virani</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Polsani</surname>
<given-names>V. R.</given-names>
</name>
<name>
<surname>Nambi</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Novel markers of inflammation in atherosclerosis</article-title>. <source>Current Atherosclerosis Reports</source>, <volume>10</volume>, <fpage>164</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr57-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Washburn</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Jacobsen</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Sonko</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>J. O.</given-names>
</name>
<name>
<surname>Donnelly</surname>
<given-names>J. E.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>The validity of the Stanford Seven-Day Physical Activity Recall in young adults</article-title>. <source>Medicine and Science in Sports and Exercise</source>, <volume>35</volume>, <fpage>1374</fpage>–<lpage>1380</lpage>.</citation>
</ref>
<ref id="bibr58-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weisell</surname>
<given-names>R. C.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Body mass index as an indicator of obesity</article-title>. <source>Asia Pacific Journal of Clinical Nutrition</source>, <volume>11</volume>(<issue>Suppl. 8</issue>):<fpage>S681</fpage>–<lpage>684</lpage>.</citation>
</ref>
<ref id="bibr59-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yudkin</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Stehouwer</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Emeis</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Coppack</surname>
<given-names>S. W.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue?</article-title> <source>Arteriosclerosis, Thrombosis, and Vascular Biology</source>, <volume>19</volume>, <fpage>972</fpage>–<lpage>978</lpage>.</citation>
</ref>
<ref id="bibr60-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yusuf</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hawkin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ounpuu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bautista</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Franzosi</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Commerford</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>, … Anand</surname>
<given-names>S. S.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case–control study</article-title>. <source>Lancet</source>, <volume>366</volume>, <fpage>1640</fpage>–<lpage>1649</lpage>.</citation>
</ref>
<ref id="bibr61-1099800411405031">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zebrack</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>J. L.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Role of inflammation in cardiovascular disease: How to use C-reactive protein in clinical practice</article-title>. <source>Progress in Cardiovascular Nursing</source>, <volume>17</volume>, <fpage>174</fpage>–<lpage>185</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>